How can we bring high drug doses to the lung?

被引:65
作者
Claus, Sarah [1 ]
Weiler, Claudius [2 ]
Schiewe, Joerg [2 ]
Friess, Wolfgang [1 ]
机构
[1] Univ Munich, Dept Pharm Pharmaceut Technol & Biopharmaceut, Butenandtstr 5, D-81377 Munich, Germany
[2] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
关键词
Pulmonary drug delivery; Inhalation devices; Particle engineering; Dry powder inhalation; High dose delivery; Antibiotic inhalation; Lung delivery; DRY POWDER INHALERS; TOBRAMYCIN INHALATION POWDER; IN-VITRO DEPOSITION; CYSTIC-FIBROSIS; AEROSOL PERFORMANCE; PULMONARY DELIVERY; PARTICLE-SIZE; HEALTHY-VOLUNTEERS; FORMULATION; DEVICE;
D O I
10.1016/j.ejpb.2013.11.005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In the last decades, dry powder inhalation has become a very attractive option for pulmonary drug delivery to treat lung diseases like cystic fibroses and lung infections. In contrast to the traditional pulmonary application of drugs for asthma and chronic obstructive pulmonary disease, these therapies require higher lung doses to be administered. The developments and improvements toward high dose powder pulmonary drug delivery are summarized and discussed in this chapter. These include the invention and improvement of novel inhaler devices as well as the further development of formulation principles and new powder engineering methods. The implementation of these strategies is subsequently described for some prototypes and formulations in research and development stage as well as for already marketed dry powder products. Finally, possible adverse effects that can occur after inhalation of high powder doses are shortly addressed. (C) 2013 Elsevier B.V. All rights reserved.
引用
收藏
页码:1 / 6
页数:6
相关论文
共 86 条
  • [1] A new method for bronchial-provocation testing in asthmatic subjects using a dry powder of mannitol
    Anderson, SD
    Brannan, J
    Spring, J
    Spalding, N
    Rodwell, LT
    Chan, K
    Gonda, I
    Walsh, A
    Clark, AR
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1997, 156 (03) : 758 - 765
  • [2] [Anonymous], 2012, WC500123690 EUR MED
  • [3] [Anonymous], 2010, FACH ARID PULV INH G
  • [4] [Anonymous], 2011, FACH TOBI PODH GERM
  • [5] [Anonymous], 2011, FACH REL 5 MG DOS
  • [6] [Anonymous], RESP DRUG DELIVERY
  • [7] [Anonymous], INH VANC TOL SAF PHA
  • [8] [Anonymous], 2011, BAYER RES, V21
  • [9] Dry powder inhalers of gentamicin and leucine: formulation parameters, aerosol performance and in vitro toxicity on CuFi1 cells
    Aquino, R. P.
    Prota, L.
    Auriemma, G.
    Santoro, A.
    Mencherini, T.
    Colombo, G.
    Russo, P.
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2012, 426 (1-2) : 100 - 107
  • [10] Inhaled synthetic surfactant abolishes the early allergen-induced response in asthma
    Babu, KS
    Woodcock, DA
    Smith, SE
    Staniforth, JN
    Holgate, ST
    Conway, JH
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2003, 21 (06) : 1046 - 1049